US 11,673,890 B2
N1-pyrazolospiroketone acetyl-CoA carboxylase inhibitors
Mary Theresa Didiuk, Madison, CT (US); Robert Lee Dow, Quincy, MA (US); and David Andrew Griffith, Sudbury, MA (US)
Assigned to Pfizer Inc., New York, NY (US)
Filed by Pfizer Inc., New York, NY (US)
Filed on Sep. 28, 2020, as Appl. No. 17/34,295.
Application 17/034,295 is a continuation of application No. 16/371,896, filed on Apr. 1, 2019, granted, now 10,822,335.
Application 16/371,896 is a continuation of application No. 15/883,109, filed on Jan. 30, 2018, granted, now 10,294,225, issued on May 21, 2019.
Application 15/883,109 is a continuation of application No. 15/236,635, filed on Aug. 15, 2016, granted, now 9,908,883, issued on Mar. 6, 2018.
Application 15/236,635 is a continuation of application No. 14/491,016, filed on Sep. 19, 2014, granted, now 9,145,416, issued on Sep. 29, 2015.
Application 14/491,016 is a continuation of application No. 13/876,211, granted, now 8,859,577, issued on Oct. 14, 2014, previously published as PCT/IB2011/054119, filed on Sep. 20, 2011.
Claims priority of provisional application 61/388,102, filed on Sep. 30, 2010.
Prior Publication US 2021/0047325 A1, Feb. 18, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/435 (2006.01); C07D 471/10 (2006.01); C07D 491/20 (2006.01); C07D 519/00 (2006.01); A61K 31/438 (2006.01); A61K 31/519 (2006.01); A61K 45/06 (2006.01); C07D 487/10 (2006.01)
CPC C07D 471/10 (2013.01) [A61K 31/435 (2013.01); A61K 31/438 (2013.01); A61K 31/519 (2013.01); A61K 45/06 (2013.01); C07D 487/10 (2013.01); C07D 491/20 (2013.01); C07D 519/00 (2013.01)] 10 Claims
 
1. A method for treating a disease, condition or disorder mediated by the inhibition of acetyl-CoA carboxylase enzymes in a human, the method comprising the step of administering to the human in need of such treatment a therapeutically effective amount of a compound of structure:

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof, wherein the disease, condition or disorder is selected from the group consisting of Type I diabetes, Type II diabetes and diabetes-related diseases, nonalcoholic fatty liver disease (NAFLD), hepatic insulin resistance, hyperglycemia, metabolic syndrome, impaired glucose tolerance, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, obesity, obesity-related disorders, dyslipidemia, hypertension, hyperinsulinemia, insulin resistance syndrome, atherosclerosis, coronary heart disease, coronary artery disease, heart failure, stroke, peripheral vascular disease, nephropathy, hypertension, neuropathy, and retinopathy.